Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia
Chemotherapy-induced nausea and vomiting (CINV) affects quality of life for patients with cancer undergoing chemotherapy. We aimed to assess the effect of lorazepam with granisetron on CINV in children with acute lymphoblastic leukemia (ALL).
We reviewed the records of 71 consecutive patients with newly diagnosed ALL who received chemotherapy including vincristine, anthracycline, and systemic steroids between January 2011 and December 2016 in our hospital. The number of chemotherapy cycles reviewed was 164. All patients received granisetron as CINV prophylaxis.
Nausea was observed in 51/71 patients (72%) and 93/164 cycles (57%). Vomiting was observed in 47/71 patients (66%) and 79/164 cycles (48%). Age and gender distribution were not significantly different between patients who received lorazepam at the initiation of the chemotherapy cycle (LZP group, n = 30) and those who did not receive lorazepam (non-LZP group, n = 134). There were no significant differences in the incidence of CIN and CIV between the LZP group and non-LZP group (CIN, 67% vs. 57%, P = 0.31; CIV, 53% vs. 47%, P = 0.98). In multivariate logistic regression, female gender and older age (> 5 years) were significant risk factors for CIV (female, odds ratio (OR) 2.5, 95% confidence interval (CI) 1.3–5.0, P = 0.007; older age, OR 2.5, CI 1.3–4.8, P = 0.008).
We found no beneficial effect of providing lorazepam as adjuvant antiemetic for prevention of CINV in children with ALL.
KeywordsLorazepam Chemotherapy Nausea Vomiting Antiemetics
We would like to thank the doctors and nurses of the Department of Hematology and Oncology in Hyogo Prefectural Kobe Children’s Hospital, Japan, for their support and cooperation.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Flank J, Robinson PD, Holdsworth M, Phillips R, Portwine C, Gibson P, Maan C, Stefin N, Sung L, Dupuis LL (2016) Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. Pediatr Blood Cancer 63:1144–1151CrossRefGoogle Scholar
- 4.Rao KV, Faso A (2012) Chemotherapy-induced nausea and vomiting: optimizing prevention and management. Am Health Drug Benefits 5(4):232–240Google Scholar
- 7.Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, On behalf of the participants of the MASCC/ESMO Consensus Conference Copenhagen2015 (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(supplement 5):v119–v133CrossRefGoogle Scholar
- 8.Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(28):3240–3261CrossRefGoogle Scholar
- 9.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version 2.2017_March 28,2017. www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed Oct 4,2017
- 10.Takeuchi H, Saeki T, Aiba K, Tamura K, Aogi K, Eguchi K, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Wada M, Akechi T, Udagawa Y, Okawa Y, Onozawa Y, Sasaki H, Shima Y, Shimoyama N, Takeda M, Nishidate T, Yamamoto A, Ikeda T, Hirata K (2016) Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. Int J Clin Oncol 21(1):1–12CrossRefGoogle Scholar
- 12.Molino A, Guglielmo L, Azzolini ME, Biondani P, Capelli MC, Grandinetti A, Griso C, Martinelli G, Martini N, Zanotti R et al (1991) The antiemetic activity of high-dose metoclopramide and high-dose alizapride in combination with lorazepam in patients receiving cancer chemotherapy. A prospective, randomized, double-blind study. Oncology 48(2):111–115CrossRefGoogle Scholar
- 15.Sepúlveda-Vildósola AC, Betanzos-Cabrera Y, Lastiri GG, Rivera-Márquez H, Villasis-Keever MA, Del Angel VW, Díaz FC, López-Aguilar E (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 39(6):601–606CrossRefGoogle Scholar
- 20.Dupuis LL, Boodhan S, Holdsworth M, Robinson PD, Hain R, Portwine C, O’Shaughnessy E, Sung L. Guideline for classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Version date: February 28, 2013. http://www.pogo.ca/_media/File/guidelines/POGO%20Emetogenicity%20Classification%20Guideline%20Final-rev-%20250111.pdf. Accessed Oct 4,2017
- 22.Shillingburg A, Biondo L (2014) Aprepitant and fosaprepitant use in children and adolescent at an academic medical center. J Pediatr Phamacol Ther 19(2):127–131Google Scholar
- 24.Loeffen EAH, Kremer LCM, Mulder RL, Font-Gonzalez A, Dupuis LL, Sung L, Robinson PD, van de Wetering MD, Tissing WJE (2017) The importance of evidence-based supportive care practice guidelines in childhood cancer—a plea for their development and implementation. Support Care Cancer 25:1121–1125CrossRefGoogle Scholar
- 25.Yokoi M, Tsuji D, Suzuki K, Kawasaki Y, Nakao M, Ayuhara H, Kogure Y, Shibata K, Hayashi T, Hirai K, Inoue K, Hama T, Takeda K, Nishio M, Itoh K (2018) Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy. Support Care Cancer 26(5):1505–1513Google Scholar
- 29.Razavi D, Delvaux N, Farvacques C, De BF, Van HC, Kaufman L, Derde MP, Beauduin M, Piccart M (1993) Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 11(7):1384–1390CrossRefGoogle Scholar
- 33.Harousseau JL, Zittoun R, Bonneterre J, Hedouin M, Ouvry J (2000) Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination. Bull Cancer 87(6):491–497Google Scholar
- 34.Ahn MJ, Lee JS, Lee KH, Suh C, Choi SS, Kim SH (1994) A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy. Am J Clin Oncol 17(2):150–156CrossRefGoogle Scholar
- 35.Marx W, McCarthy AL, Ried K, McKavanagh D, Vitetta L, Sali A, Lohning A, Isenring E (2017) The effect of a standardized ginger extract on chemotherapy-induced nausea-related quality of life in patients undergoing moderately or highly emetogenic chemotherapy: a double blind, randomized, Placebo Controlled Trial. Nutrients 9(8):867CrossRefGoogle Scholar